At Idorsia, we follow the science – which often leads us to seek input from a variety of perspectives. We value collaboration with academia, industry partners, governments, NGOs, and others, to help us find solutions to scientific challenges.
In order to promote innovation, enhance productivity, and accelerate delivery of new medicines, we engage in mutually beneficial strategic partnerships. By partnering, we can maximize the potential of our assets, improve the lives of patients in need of our therapies, and have a greater positive impact for all stakeholders.
Strategic partnerships – including collaborative research and development, and commercialization agreements – are a way of fully exploiting our discovery engine and clinical pipeline. Several of our strategic partnerships involve milestone payments based on the progress of the development compound in question, and/or revenue-sharing agreements, under which we are eligible to receive royalty payments as a proportion of net sales.
We have also entered into partnerships to gain access to technologies or services that are not part of our company’s core capabilities, such as our agreement with Syneos Health for the US and EUCAN sales force to support the launch of QUVIVIQ and co-promotion partnerships with Menarini and Berlin-Chemie to extend our commercial reach to GPs in France and Germany respectively. Our strategic partnerships are overseen by the Chief Executive Officer in collaboration with the appropriate executive member of the internal research, development, or commercial organization leading the partnership.
